{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:16:40Z","timestamp":1789661800431,"version":"4.0.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"DOI":"10.1186\/s13195-026-02045-0","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T03:09:55Z","timestamp":1776827395000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Plasma biomarker trajectories across Alzheimer\u2019s clinical onset: a 17-year prospective study"],"prefix":"10.1186","volume":"18","author":[{"given":"Siqi","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumei","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yana","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuman","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhay","family":"Moghekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilyn","family":"Albert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"BIOCARD Study team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Rodzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Soldan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Pettigrew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonie","family":"Farrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura","family":"Grega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilak","family":"Ratnanather","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Kolasny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanzhang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Oishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Younes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Grace","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Shade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Ervin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamadou","family":"Coulibaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Cheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangxia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Troncoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Nauen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"issue":"3","key":"2045_CR1","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the national institute on aging-Alzheimer\u2019s association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):280\u201392. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.003.","journal-title":"Alzheimers Dement"},{"issue":"10","key":"2045_CR2","doi-asserted-by":"publisher","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","volume":"26","author":"H Hampel","year":"2021","unstructured":"Hampel H, Hardy J, Blennow K, Chen C, Perry G, Kim SH, et al. The amyloid-beta pathway in alzheimer\u2019s disease. Mol Psychiatry. 2021;26(10):5481\u2013503. https:\/\/doi.org\/10.1038\/s41380-021-01249-0.","journal-title":"Mol Psychiatry"},{"issue":"5580","key":"2045_CR3","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"J Hardy","year":"2002","unstructured":"Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353\u20136. https:\/\/doi.org\/10.1126\/science.1072994.","journal-title":"Science"},{"issue":"5054","key":"2045_CR4","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1126\/science.1566067","volume":"256","author":"JA Hardy","year":"1992","unstructured":"Hardy JA, Higgins GA. Alzheimer\u2019s disease: the amyloid cascade hypothesis. Science. 1992;256(5054):184\u20135. https:\/\/doi.org\/10.1126\/science.1566067.","journal-title":"Science"},{"issue":"5","key":"2045_CR5","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s43587-023-00403-3","volume":"3","author":"O Hansson","year":"2023","unstructured":"Hansson O, Blennow K, Zetterberg H, Dage J. Blood biomarkers for Alzheimer\u2019s disease in clinical practice and trials. Nat Aging. 2023;3(5):506\u201319. https:\/\/doi.org\/10.1038\/s43587-023-00403-3.","journal-title":"Nat Aging"},{"issue":"5","key":"2045_CR6","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/s43587-023-00400-6","volume":"3","author":"SE Schindler","year":"2023","unstructured":"Schindler SE, Atri A. The role of cerebrospinal fluid and other biomarker modalities in the Alzheimer\u2019s disease diagnostic revolution. Nat Aging. 2023;3(5):460\u20132. https:\/\/doi.org\/10.1038\/s43587-023-00400-6.","journal-title":"Nat Aging"},{"issue":"8","key":"2045_CR7","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr.","year":"2024","unstructured":"Jack CR Jr., Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s association workgroup. Alzheimers Dement. 2024;20(8):5143\u201369. https:\/\/doi.org\/10.1002\/alz.13859.","journal-title":"Alzheimers Dement"},{"issue":"9","key":"2045_CR8","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1202753","volume":"367","author":"RJ Bateman","year":"2012","unstructured":"Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease. N Engl J Med. 2012;367(9):795\u2013804. https:\/\/doi.org\/10.1056\/NEJMoa1202753.","journal-title":"N Engl J Med"},{"issue":"14","key":"2045_CR9","doi-asserted-by":"publisher","first-page":"e1295","DOI":"10.1212\/WNL.0000000000006277","volume":"91","author":"E McDade","year":"2018","unstructured":"McDade E, Wang G, Gordon BA, Hassenstab J, Benzinger TLS, Buckles V, et al. Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. Neurology. 2018;91(14):e1295\u2013306. https:\/\/doi.org\/10.1212\/WNL.0000000000006277.","journal-title":"Neurology"},{"issue":"5","key":"2045_CR10","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jalz.2018.12.019","volume":"15","author":"SE Schindler","year":"2019","unstructured":"Schindler SE, Li Y, Todd KW, Herries EM, Henson RL, Gray JD, et al. Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer\u2019s disease. Alzheimers Dement. 2019;15(5):655\u201365. https:\/\/doi.org\/10.1016\/j.jalz.2018.12.019.","journal-title":"Alzheimers Dement"},{"issue":"226","key":"2045_CR11","doi-asserted-by":"publisher","first-page":"226ra30","DOI":"10.1126\/scitranslmed.3007901","volume":"6","author":"AM Fagan","year":"2014","unstructured":"Fagan AM, Xiong C, Jasielec MS, Bateman RJ, Goate AM, Benzinger TL, et al. Longitudinal change in csf biomarkers in autosomal-dominant Alzheimer\u2019s disease. Sci Transl Med. 2014;6(226):226ra30. https:\/\/doi.org\/10.1126\/scitranslmed.3007901.","journal-title":"Sci Transl Med"},{"issue":"2","key":"2045_CR12","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","volume":"12","author":"CR Jack","year":"2013","unstructured":"Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer\u2019s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207\u201316. https:\/\/doi.org\/10.1016\/S1474-4422(12)70291-0.","journal-title":"Lancet Neurol"},{"issue":"1","key":"2045_CR13","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","volume":"9","author":"CR Jack","year":"2010","unstructured":"Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer\u2019s pathological cascade. Lancet Neurol. 2010;9(1):119\u201328. https:\/\/doi.org\/10.1016\/S1474-4422(09)70299-6.","journal-title":"Lancet Neurol"},{"issue":"8","key":"2045_CR14","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1056\/NEJMoa2310168","volume":"390","author":"J Jia","year":"2024","unstructured":"Jia J, Ning Y, Chen M, Wang S, Yang H, Li F, et al. Biomarker changes during 20 years preceding Alzheimer\u2019s disease. N Engl J Med. 2024;390(8):712\u201322. https:\/\/doi.org\/10.1056\/NEJMoa2310168.","journal-title":"N Engl J Med"},{"issue":"8","key":"2045_CR15","doi-asserted-by":"publisher","first-page":"e70544","DOI":"10.1002\/alz.70544","volume":"21","author":"Y Uchida","year":"2025","unstructured":"Uchida Y, Nishimaki K, Soldan A, Pettigrew C, Ho SG, Moghekar A, et al. Change points for dynamic biomarkers in the Alzheimer\u2019s disease pathological cascade: a 30-year cohort study. Alzheimers Dement. 2025;21(8):e70544. https:\/\/doi.org\/10.1002\/alz.70544.","journal-title":"Alzheimers Dement"},{"issue":"8","key":"2045_CR16","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41582-024-00989-1","volume":"20","author":"MM Mielke","year":"2024","unstructured":"Mielke MM, Fowler NR. Alzheimer disease blood biomarkers: considerations for population-level use. Nat Rev Neurol. 2024;20(8):495\u2013504. https:\/\/doi.org\/10.1038\/s41582-024-00989-1.","journal-title":"Nat Rev Neurol"},{"issue":"10","key":"2045_CR17","doi-asserted-by":"publisher","first-page":"4335","DOI":"10.1002\/alz.13157","volume":"19","author":"M Bilgel","year":"2023","unstructured":"Bilgel M, An Y, Walker KA, Moghekar AR, Ashton NJ, Kac PR, et al. Longitudinal changes in Alzheimer\u2019s-related plasma biomarkers and brain amyloid. Alzheimers Dement. 2023;19(10):4335\u201345. https:\/\/doi.org\/10.1002\/alz.13157.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"2045_CR18","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1002\/ana.27285","volume":"98","author":"M Mila-Aloma","year":"2025","unstructured":"Mila-Aloma M, Tosun D, Schindler SE, Hausle I, Petersen KK, Li Y, et al. Timing of changes in Alzheimer\u2019s disease plasma biomarkers as assessed by amyloid and tau pet clocks. Ann Neurol. 2025;98(3):508\u201323. https:\/\/doi.org\/10.1002\/ana.27285.","journal-title":"Ann Neurol"},{"key":"2045_CR19","doi-asserted-by":"publisher","unstructured":"Raket LL, Pichet Binette A, Mattsson-Carlgren N, Janelidze S, Zetterberg H, Ashton NJ, et al. Estimating the time course of biomarker changes in Alzheimer's disease. Brain. 2025. https:\/\/doi.org\/10.1093\/brain\/awaf413.","DOI":"10.1093\/brain\/awaf413"},{"issue":"4","key":"2045_CR20","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S1474-4422(13)70044-9","volume":"12","author":"VL Villemagne","year":"2013","unstructured":"Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid \u03b2 deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer\u2019s disease: a prospective cohort study. Lancet Neurol. 2013;12(4):357\u201367. https:\/\/doi.org\/10.1016\/S1474-4422(13)70044-9.","journal-title":"Lancet Neurol"},{"issue":"10","key":"2045_CR21","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1212\/WNL.0b013e3182840bbe","volume":"80","author":"CR Jack Jr","year":"2013","unstructured":"Jack CR Jr, Wiste HJ, Lesnick TG, Weigand SD, Knopman DS, Vemuri P, et al. Brain beta-amyloid load approaches a plateau. Neurology. 2013;80(10):890\u20136. https:\/\/doi.org\/10.1212\/WNL.0b013e3182840bbe.","journal-title":"Neurology"},{"key":"2045_CR22","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.nicl.2013.02.006","volume":"2","author":"G Chetelat","year":"2013","unstructured":"Chetelat G, La Joie R, Villain N, Perrotin A, de La Sayette V, Eustache F, et al. Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer\u2019s disease. Neuroimage Clin. 2013;2:356\u201365. https:\/\/doi.org\/10.1016\/j.nicl.2013.02.006.","journal-title":"Neuroimage Clin"},{"issue":"2","key":"2045_CR23","doi-asserted-by":"publisher","first-page":"e210225","DOI":"10.1212\/WNL.0000000000210225","volume":"104","author":"A Soldan","year":"2025","unstructured":"Soldan A, Pettigrew C, Wang J, Albert MS, Blennow K, Bittner T, et al. Blood-based biomarkers and risk of onset of mild cognitive impairment over the short and long term. Neurology. 2025;104(2):e210225. https:\/\/doi.org\/10.1212\/WNL.0000000000210225.","journal-title":"Neurology"},{"issue":"1","key":"2045_CR24","doi-asserted-by":"publisher","first-page":"e70081","DOI":"10.1002\/dad2.70081","volume":"17","author":"C Pettigrew","year":"2025","unstructured":"Pettigrew C, Soldan A, Wang J, Hohman T, Dumitrescu L, Albert M, et al. Plasma biomarker trajectories: impact of ad genetic risk and clinical progression. Alzheimers Dement (Amst). 2025;17(1):e70081. https:\/\/doi.org\/10.1002\/dad2.70081.","journal-title":"Alzheimers Dement (Amst)"},{"issue":"8","key":"2045_CR25","doi-asserted-by":"publisher","first-page":"773","DOI":"10.2174\/156720501108140910121920","volume":"11","author":"M Albert","year":"2014","unstructured":"Albert M, Soldan A, Gottesman R, McKhann G, Sacktor N, Farrington L, et al. Cognitive changes preceding clinical symptom onset of mild cognitive impairment and relationship to apoe genotype. Curr Alzheimer Res. 2014;11(8):773\u201384. https:\/\/doi.org\/10.2174\/156720501108140910121920.","journal-title":"Curr Alzheimer Res"},{"issue":"3","key":"2045_CR26","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):263\u20139. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.005.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"2045_CR27","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):270\u20139. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.008.","journal-title":"Alzheimers Dement"},{"issue":"6","key":"2045_CR28","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1001\/jamaneurol.2016.0194","volume":"73","author":"A Soldan","year":"2016","unstructured":"Soldan A, Pettigrew C, Cai Q, Wang MC, Moghekar AR, O\u2019Brien RJ, et al. Hypothetical preclinical Alzheimer disease groups and longitudinal cognitive change. JAMA Neurol. 2016;73(6):698\u2013705. https:\/\/doi.org\/10.1001\/jamaneurol.2016.0194.","journal-title":"JAMA Neurol"},{"key":"2045_CR29","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.bbi.2020.01.006","volume":"87","author":"KA Walker","year":"2020","unstructured":"Walker KA, Gross AL, Moghekar AR, Soldan A, Pettigrew C, Hou X, et al. Association of peripheral inflammatory markers with connectivity in large-scale functional brain networks of non-demented older adults. Brain Behav Immun. 2020;87:388\u201396. https:\/\/doi.org\/10.1016\/j.bbi.2020.01.006.","journal-title":"Brain Behav Immun"},{"key":"2045_CR30","doi-asserted-by":"publisher","unstructured":"Arslan B, Brum WS, Pola I, Therriault J, Rahmouni N, Stevenson J, et al. The impact of kidney function on Alzheimer\u2019s disease blood biomarkers: implications for predicting amyloid-\u03b2 positivity. Alz Res Ther. 2025;17(1). https:\/\/doi.org\/10.1186\/s13195-025-01692-z.","DOI":"10.1186\/s13195-025-01692-z"},{"key":"2045_CR31","doi-asserted-by":"publisher","unstructured":"Janelidze S, Barth\u00e9lemy NR, He Y, Bateman RJ, Hansson O. Mitigating the associations of kidney dysfunction with blood biomarkers of Alzheimer disease by using phosphorylated tau to total tau ratios. JAMA Neurol. 2023;80(5). https:\/\/doi.org\/10.1001\/jamaneurol.2023.0199.","DOI":"10.1001\/jamaneurol.2023.0199"},{"key":"2045_CR32","doi-asserted-by":"publisher","unstructured":"Bermudez C, Syrjanen JA, Stricker NH, Algeciras-Schimnich A, Kouri N, Kremers WK, et al. Impact of cardiovascular risk factors on plasma biomarkers in prediction of Alzheimer's and cerebrovascular neuropathology. J Prev Alzheimer\u2019s Dis. 2025;12(8). https:\/\/doi.org\/10.1016\/j.tjpad.2025.100224.","DOI":"10.1016\/j.tjpad.2025.100224"},{"issue":"14","key":"2045_CR33","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1001\/jama.2017.3090","volume":"317","author":"RF Gottesman","year":"2017","unstructured":"Gottesman RF, Schneider AL, Zhou Y, Coresh J, Green E, Gupta N, et al. Association between midlife vascular risk factors and estimated brain amyloid deposition. JAMA. 2017;317(14):1443\u201350. https:\/\/doi.org\/10.1001\/jama.2017.3090.","journal-title":"JAMA"},{"issue":"18","key":"2045_CR34","doi-asserted-by":"publisher","first-page":"e1823","DOI":"10.1212\/WNL.0000000000012775","volume":"97","author":"SE Schindler","year":"2021","unstructured":"Schindler SE, Li Y, Buckles VD, Gordon BA, Benzinger TLS, Wang G, et al. Predicting symptom onset in sporadic Alzheimer disease with amyloid pet. Neurology. 2021;97(18):e1823\u201334. https:\/\/doi.org\/10.1212\/WNL.0000000000012775.","journal-title":"Neurology"},{"issue":"5","key":"2045_CR35","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1002\/ana.26891","volume":"95","author":"Y Li","year":"2024","unstructured":"Li Y, Yen D, Hendrix RD, Gordon BA, Dlamini S, Barthelemy NR, et al. Timing of biomarker changes in sporadic Alzheimer\u2019s disease in estimated years from symptom onset. Ann Neurol. 2024;95(5):951\u201365. https:\/\/doi.org\/10.1002\/ana.26891.","journal-title":"Ann Neurol"},{"issue":"8","key":"2045_CR36","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1002\/alz.13909","volume":"20","author":"J Vogelgsang","year":"2024","unstructured":"Vogelgsang J, Hansen N, Stark M, Wagner M, Klafki H, Morgado BM, et al. Plasma amyloid beta x-42\/x-40 ratio and cognitive decline in suspected early and preclinical Alzheimer\u2019s disease. Alzheimers Dement. 2024;20(8):5132\u201342. https:\/\/doi.org\/10.1002\/alz.13909.","journal-title":"Alzheimers Dement"},{"issue":"7","key":"2045_CR37","doi-asserted-by":"publisher","first-page":"e688","DOI":"10.1212\/WNL.0000000000013211","volume":"98","author":"Y Li","year":"2022","unstructured":"Li Y, Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Weiner MW, et al. Validation of plasma amyloid-beta 42\/40 for detecting Alzheimer disease amyloid plaques. Neurology. 2022;98(7):e688\u201399. https:\/\/doi.org\/10.1212\/WNL.0000000000013211.","journal-title":"Neurology"},{"issue":"6","key":"2045_CR38","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","volume":"27","author":"O Hansson","year":"2021","unstructured":"Hansson O. Biomarkers for neurodegenerative diseases. Nat Med. 2021;27(6):954\u201363. https:\/\/doi.org\/10.1038\/s41591-021-01382-x.","journal-title":"Nat Med"},{"issue":"9","key":"2045_CR39","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1007\/s10072-023-06882-x","volume":"44","author":"F Verde","year":"2023","unstructured":"Verde F, Milone I, Dubini A, Colombrita C, Perego A, Solca F, et al. Influence of kidney function and csf\/serum albumin ratio on plasma abeta42 and abeta40 levels measured on a fully automated platform in patients with Alzheimer\u2019s disease. Neurol Sci. 2023;44(9):3287\u201390. https:\/\/doi.org\/10.1007\/s10072-023-06882-x.","journal-title":"Neurol Sci"},{"issue":"1","key":"2045_CR40","doi-asserted-by":"publisher","first-page":"e12405","DOI":"10.1002\/dad2.12405","volume":"15","author":"JK Wisch","year":"2023","unstructured":"Wisch JK, Gordon BA, Boerwinkle AH, Luckett PH, Bollinger JG, Ovod V, et al. Predicting continuous amyloid pet values with csf and plasma abeta42\/abeta40. Alzheimers Dement (Amst). 2023;15(1):e12405. https:\/\/doi.org\/10.1002\/dad2.12405.","journal-title":"Alzheimers Dement (Amst)"},{"issue":"2","key":"2045_CR41","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/jamaneurol.2023.4719","volume":"81","author":"WS Brum","year":"2024","unstructured":"Brum WS, Docherty KF, Ashton NJ, Zetterberg H, Hansson O, McMurray JJV, et al. Effect of neprilysin inhibition on Alzheimer disease plasma biomarkers: a secondary analysis of a randomized clinical trial. JAMA Neurol. 2024;81(2):197\u2013200. https:\/\/doi.org\/10.1001\/jamaneurol.2023.4719.","journal-title":"JAMA Neurol"},{"issue":"1","key":"2045_CR42","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13024-024-00711-1","volume":"19","author":"X Zeng","year":"2024","unstructured":"Zeng X, Chen Y, Sehrawat A, Lee J, Lafferty TK, Kofler J, et al. Alzheimer blood biomarkers: practical guidelines for study design, sample collection, processing, biobanking, measurement and result reporting. Mol Neurodegener. 2024;19(1):40. https:\/\/doi.org\/10.1186\/s13024-024-00711-1.","journal-title":"Mol Neurodegener"},{"issue":"1","key":"2045_CR43","doi-asserted-by":"publisher","first-page":"e16226","DOI":"10.1111\/jnc.16226","volume":"169","author":"D Gogishvili","year":"2025","unstructured":"Gogishvili D, Honey MIJ, Verberk IMW, Vermunt L, Hol EM, Teunissen CE, et al. The gfap proteoform puzzle: how to advance gfap as a fluid biomarker in neurological diseases. J Neurochem. 2025;169(1):e16226. https:\/\/doi.org\/10.1111\/jnc.16226.","journal-title":"J Neurochem"},{"issue":"1","key":"2045_CR44","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13195-022-01093-6","volume":"14","author":"S Baiardi","year":"2022","unstructured":"Baiardi S, Quadalti C, Mammana A, Dellavalle S, Zenesini C, Sambati L, et al. Diagnostic value of plasma p-tau181, nfl, and gfap in a clinical setting cohort of prevalent neurodegenerative dementias. Alzheimers Res Ther. 2022;14(1):153. https:\/\/doi.org\/10.1186\/s13195-022-01093-6.","journal-title":"Alzheimers Res Ther"},{"key":"2045_CR45","doi-asserted-by":"publisher","unstructured":"Yang Z, Arja RD, Zhu T, Sarkis GA, Patterson RL, Romo P, et al. Characterization of calpain and caspase-6-generated glial fibrillary acidic protein breakdown products following traumatic brain injury and astroglial cell injury. Int J Mol Sci. 2022;23(16). https:\/\/doi.org\/10.3390\/ijms23168960.","DOI":"10.3390\/ijms23168960"},{"issue":"10","key":"2045_CR46","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1002\/alz.12806","volume":"18","author":"J Simren","year":"2022","unstructured":"Simren J, Weninger H, Brum WS, Khalil S, Benedet AL, Blennow K, et al. Differences between blood and cerebrospinal fluid glial fibrillary acidic protein levels: the effect of sample stability. Alzheimers Dement. 2022;18(10):1988\u201392. https:\/\/doi.org\/10.1002\/alz.12806.","journal-title":"Alzheimers Dement"},{"issue":"5","key":"2045_CR47","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1002\/prot.26656","volume":"92","author":"D Gogishvili","year":"2024","unstructured":"Gogishvili D, Illes-Toth E, Harris MJ, Hopley C, Teunissen CE, Abeln S. Structural flexibility and heterogeneity of recombinant human glial fibrillary acidic protein (gfap). Proteins. 2024;92(5):649\u201364. https:\/\/doi.org\/10.1002\/prot.26656.","journal-title":"Proteins"},{"issue":"12","key":"2045_CR48","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1001\/jamaneurol.2021.3671","volume":"78","author":"AL Benedet","year":"2021","unstructured":"Benedet AL, Mila-Aloma M, Vrillon A, Ashton NJ, Pascoal TA, Lussier F, et al. Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum. JAMA Neurol. 2021;78(12):1471\u201383. https:\/\/doi.org\/10.1001\/jamaneurol.2021.3671.","journal-title":"JAMA Neurol"},{"issue":"7","key":"2045_CR49","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1002\/alz.12879","volume":"19","author":"P Chatterjee","year":"2023","unstructured":"Chatterjee P, Vermunt L, Gordon BA, Pedrini S, Boonkamp L, Armstrong NJ, et al. Plasma glial fibrillary acidic protein in autosomal dominant Alzheimer\u2019s disease: Associations with abeta-pet, neurodegeneration, and cognition. Alzheimers Dement. 2023;19(7):2790\u2013804. https:\/\/doi.org\/10.1002\/alz.12879.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"2045_CR50","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13195-015-0142-1","volume":"7","author":"MI Kester","year":"2015","unstructured":"Kester MI, Teunissen CE, Sutphen C, Herries EM, Ladenson JH, Xiong C, et al. Cerebrospinal fluid vilip-1 and ykl-40, candidate biomarkers to diagnose, predict and monitor Alzheimer\u2019s disease in a memory clinic cohort. Alzheimers Res Ther. 2015;7(1):59. https:\/\/doi.org\/10.1186\/s13195-015-0142-1.","journal-title":"Alzheimers Res Ther"},{"issue":"10","key":"2045_CR51","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.biopsych.2010.08.025","volume":"68","author":"R Craig-Schapiro","year":"2010","unstructured":"Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, et al. Ykl-40: a novel prognostic fluid biomarker for preclinical Alzheimer\u2019s disease. Biol Psychiatry. 2010;68(10):903\u201312. https:\/\/doi.org\/10.1016\/j.biopsych.2010.08.025.","journal-title":"Biol Psychiatry"},{"issue":"1","key":"2045_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13024-018-0301-5","volume":"14","author":"M Suarez-Calvet","year":"2019","unstructured":"Suarez-Calvet M, Morenas-Rodriguez E, Kleinberger G, Schlepckow K, Araque Caballero MA, Franzmeier N, et al. Early increase of csf strem2 in Alzheimer\u2019s disease is associated with tau related-neurodegeneration but not with amyloid-beta pathology. Mol Neurodegener. 2019;14(1):1. https:\/\/doi.org\/10.1186\/s13024-018-0301-5.","journal-title":"Mol Neurodegener"},{"issue":"1","key":"2045_CR53","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13195-022-01051-2","volume":"14","author":"S Prins","year":"2022","unstructured":"Prins S, de Kam ML, Teunissen CE, Groeneveld GJ. Inflammatory plasma biomarkers in subjects with preclinical Alzheimer\u2019s disease. Alzheimers Res Ther. 2022;14(1):106. https:\/\/doi.org\/10.1186\/s13195-022-01051-2.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"2045_CR54","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13195-022-01118-0","volume":"15","author":"F Brosseron","year":"2023","unstructured":"Brosseron F, Maass A, Kleineidam L, Ravichandran KA, Kolbe CC, Wolfsgruber S, et al. Serum il-6, saxl, and ykl-40 as systemic correlates of reduced brain structure and function in Alzheimer\u2019s disease: results from the delcode study. Alzheimers Res Ther. 2023;15(1):13. https:\/\/doi.org\/10.1186\/s13195-022-01118-0.","journal-title":"Alzheimers Res Ther"},{"key":"2045_CR55","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jneuroim.2018.03.003","volume":"319","author":"LM Bekris","year":"2018","unstructured":"Bekris LM, Khrestian M, Dyne E, Shao Y, Pillai JA, Rao SM, et al. Soluble trem2 and biomarkers of central and peripheral inflammation in neurodegenerative disease. J Neuroimmunol. 2018;319:19\u201327. https:\/\/doi.org\/10.1016\/j.jneuroim.2018.03.003.","journal-title":"J Neuroimmunol"},{"issue":"11","key":"2045_CR56","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1093\/brain\/awab332","volume":"144","author":"HH Tsai","year":"2021","unstructured":"Tsai HH, Chen YF, Yen RF, Lo YL, Yang KC, Jeng JS, et al. Plasma soluble trem2 is associated with white matter lesions independent of amyloid and tau. Brain. 2021;144(11):3371\u201380. https:\/\/doi.org\/10.1093\/brain\/awab332.","journal-title":"Brain"},{"issue":"11","key":"2045_CR57","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1093\/rheumatology\/32.11.949","volume":"32","author":"JS Johansen","year":"1993","unstructured":"Johansen JS, Jensen HS, Price PA. A new biochemical marker for joint injury. Analysis of ykl-40 in serum and synovial fluid. Br J Rheumatol. 1993;32(11):949\u201355. https:\/\/doi.org\/10.1093\/rheumatology\/32.11.949.","journal-title":"Br J Rheumatol"},{"issue":"1","key":"2045_CR58","first-page":"5","volume":"51","author":"MH Kazakova","year":"2009","unstructured":"Kazakova MH, Sarafian VS. Ykl-40--a novel biomarker in clinical practice? Folia Med (Plovdiv). 2009;51(1):5\u201314.","journal-title":"Folia Med (Plovdiv)"},{"issue":"1","key":"2045_CR59","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12974-025-03432-4","volume":"22","author":"BM Bettcher","year":"2025","unstructured":"Bettcher BM, de Oliveira FF, Willette AA, Michalowska MM, Machado LS, Rajbanshi B, et al. Analysis and interpretation of inflammatory fluid markers in Alzheimer\u2019s disease: a roadmap for standardization. J Neuroinflammation. 2025;22(1):105. https:\/\/doi.org\/10.1186\/s12974-025-03432-4.","journal-title":"J Neuroinflammation"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-026-02045-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-026-02045-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-026-02045-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T02:40:13Z","timestamp":1780454413000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13195-026-02045-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2045"],"URL":"https:\/\/doi.org\/10.1186\/s13195-026-02045-0","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"assertion":[{"value":"5 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from study participants before enrollment at both the NIH and JHU.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"137"}}